All In MedTech

Device Trial Radar · NCT06939907

Clinical Trial to Evaluate the Efficacy and Safety of Nexpowder™ for Diverticular Bleeding in the Lower Gastrointestinal Tract

Clinical Trial to Evaluate the Efficacy and Safety of Nexpowder™ for Diverticular Bleeding in the Lower Gastrointestinal Tract: A Prospective, Multi-Center, Single-Arm, Open-Label, Pilot Clinical Trial

Last checked: Nov 19, 2026Latest source record: Apr 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Jun 2025

Primary completion

Jun 2027

Study completion Jul 2027

Sponsor

Lead sponsor
Next Biomedical Co., Ltd.Not on our public-company list
Sponsor type
Industry
First posted
Apr 23, 2025

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 19 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Clinical Trial to Evaluate the Efficacy and Safety of Nexpowder™ for Diverticular Bleeding in the Lower Gastrointestinal Tract

Conditions

  • Lower Gastrointestinal Bleeding
  • Diverticular Bleeding

Interventions

  • Nexpowder™Device

    Nexpowder™ hemostatic powder

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rebleeding rateTime frame: 30 days post treatment

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Chungbuk National University Hospital

    Cheongju-si, South Korea

  • Chungnam National University Hospital

    Daejeon, South Korea

  • Chosun University Hospital

    Gwangju, South Korea

3 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.